Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.39

€0.39

-0.260%
-0.001
-0.260%
-
 
16.04.24 / Stuttgart Stock Exchange WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Gensight Biologics SA Stock

Gensight Biologics SA shows a slight decrease today, losing -€0.001 (-0.260%) compared to yesterday.
Our community identified positive and negative aspects for Gensight Biologics SA stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Gensight Biologics SA stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Gensight Biologics SA in the next few years

Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Gensight Biologics SA vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Gensight Biologics SA -0.260% 0.654% -16.395% -83.925% -13.093% -94.801% -79.758%
CEL-SCI Corp. -3.770% -10.364% -24.895% -35.721% -44.690% -90.259% -
India Globalization Capital 14.290% -14.894% 44.928% 49.254% 52.672% -67.690% -74.253%
BioInvent International AB 3.550% 1.365% 9.960% -36.544% -0.366% -67.898% -49.646%

Comments

Prediction Buy
Perf. (%) 143.05%
Target price 1.520
Change
Ends at 15.01.20

Buy closed
Show more

Buy Gensight Biologics SA
Show more

Prediction Buy
Perf. (%) 143.05%
Target price 1.520
Change
Ends at 15.01.20

Buy with target price 1.52
Show more

News

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update


Regulatory News:



GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing

GenSight Biologics Announces its 2024 Financial Calendar: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces its 2024 Financial Calendar


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal